Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Kovaltry vs Advate in Severe Hemophilia A
NCT02483208Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2015
- Primary completion
- Jul 2015
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of damoctocog alfa pegol in hemophilia A (2 arms), sponsored by Bayer. Primary endpoint: Area Under the Curve from time 0 to the last data point at 48 hours. Started Jun 2015; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02483208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483208.